Ecor1 Capital, Llc - Net Worth and Insider Trading

Ecor1 Capital, Llc Net Worth

The estimated net worth of Ecor1 Capital, Llc is at least $790 Million dollars as of 2024-02-28. Ecor1 Capital, Llc is the 10% Owner of Prothena Corp PLC and owns about 11,584,280 shares of Prothena Corp PLC (PRTA) stock worth over $351 Million. Ecor1 Capital, Llc is the 10% Owner of AnaptysBio Inc and owns about 7,521,024 shares of AnaptysBio Inc (ANAB) stock worth over $199 Million. Ecor1 Capital, Llc is also the 10% Owner of Zymeworks Inc and owns about 13,437,473 shares of Zymeworks Inc (ZYME) stock worth over $173 Million. Besides these, Ecor1 Capital, Llc also holds Voyager Therapeutics Inc (VYGR) , Akouos Inc (AKUS) , Surface Oncology Inc (SURF) , Corvus Pharmaceuticals Inc (CRVS) , Odonate Inc (ODTC) . Details can be seen in Ecor1 Capital, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ecor1 Capital, Llc has not made any transactions after 2023-06-16 and currently still holds the listed stock(s).

Transaction Summary of Ecor1 Capital, Llc

To

Ecor1 Capital, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ecor1 Capital, Llc owns 17 companies in total, including Surface Oncology Inc () , Panacea Acquisition Corp () , and Akouos Inc () among others .

Click here to see the complete history of Ecor1 Capital, Llc’s form 4 insider trades.

Insider Ownership Summary of Ecor1 Capital, Llc

Ticker Comapny Transaction Date Type of Owner
Surface Oncology Inc 2020-09-01 10 percent owner
Panacea Acquisition Corp 2020-07-06 director & 10 percent owner
Akouos Inc 2020-06-30 10 percent owner
Prothena Corp PLC 2022-05-05 10 percent owner
Eiger BioPharmaceuticals Inc 2015-06-26 10 percent owner
Genvec Inc 2014-05-22 10 percent owner
AnaptysBio Inc 2022-05-05 10 percent owner
Corvus Pharmaceuticals Inc 2021-10-01 10 percent owner
Voyager Therapeutics Inc 2023-01-11 10 percent owner
Odonate Inc 2021-12-10 10 percent owner
Nuvation Bio Inc 2023-02-19 director
Panacea Acquisition Corp II 2023-04-28 director & 10 percent owner
Graphite Bio Inc 2023-01-06 10 percent owner
Zymeworks Inc 2023-06-16 10 percent owner
TScan Therapeutics Inc 2023-05-26 10 percent owner
Mersana Therapeutics Inc 2023-07-27 10 percent owner
Tango Therapeutics Inc 2023-10-13 10 percent owner

Ecor1 Capital, Llc Latest Holdings Summary

Ecor1 Capital, Llc currently owns a total of 8 stocks. Among these stocks, Ecor1 Capital, Llc owns 11,584,280 shares of Prothena Corp PLC (PRTA) as of May 5, 2022, with a value of $351 Million and a weighting of 44.47%. Ecor1 Capital, Llc owns 7,521,024 shares of AnaptysBio Inc (ANAB) as of May 5, 2022, with a value of $199 Million and a weighting of 25.24%. Ecor1 Capital, Llc also owns 13,437,473 shares of Zymeworks Inc (ZYME) as of June 16, 2023, with a value of $173 Million and a weighting of 21.95%. The other 5 stocks Voyager Therapeutics Inc (VYGR) , Akouos Inc (AKUS) , Surface Oncology Inc (SURF) , Corvus Pharmaceuticals Inc (CRVS) , Odonate Inc (ODTC) have a combined weighting of 8.34% among all his current holdings.

Latest Holdings of Ecor1 Capital, Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRTA Prothena Corp PLC 2022-05-05 11,584,280 30.32 351,235,370
ANAB AnaptysBio Inc 2022-05-05 7,521,024 26.51 199,382,346
ZYME Zymeworks Inc 2023-06-16 13,437,473 12.90 173,343,402
VYGR Voyager Therapeutics Inc 2023-01-11 3,851,507 8.92 34,355,442
AKUS Akouos Inc 2020-06-30 1,975,984 13.29 26,260,827
SURF Surface Oncology Inc 2020-09-01 4,701,081 1.07 5,030,157
CRVS Corvus Pharmaceuticals Inc 2021-10-01 81,077 2.36 191,342
ODTC Odonate Inc 2021-12-10 0 3,350.00 0

Holding Weightings of Ecor1 Capital, Llc


Ecor1 Capital, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 8 transactions in Prothena Corp PLC (PRTA) over the past 5 years, including 7 buys and 1 sells. The most-recent trade in Prothena Corp PLC is the sale of 1,062,736 shares on May 5, 2022, which brought Ecor1 Capital, Llc around $31 Million.

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 5 transactions in AnaptysBio Inc (ANAB) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in AnaptysBio Inc is the sale of 668,237 shares on May 5, 2022, which brought Ecor1 Capital, Llc around $14 Million.

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 5 transactions in Zymeworks Inc (ZYME) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Zymeworks Inc is the acquisition of 3,350,000 shares on June 16, 2023, which cost Ecor1 Capital, Llc around $27 Million.

More details on Ecor1 Capital, Llc's insider transactions can be found in the Insider Trading History of Ecor1 Capital, Llc table.

Insider Trading History of Ecor1 Capital, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ecor1 Capital, Llc Trading Performance

GuruFocus tracks the stock performance after each of Ecor1 Capital, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ecor1 Capital, Llc is 6.57%. GuruFocus also compares Ecor1 Capital, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ecor1 Capital, Llc within 3 months outperforms 7 times out of 19 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ecor1 Capital, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ecor1 Capital, Llc

Average Relative Return

36.03%

Average relative return per transaction

Outperforming Transactions

71%

12 out of 17 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -2.48 6.57 48.04 36.03 16.55 4.3
Relative Return to S&P 500(%) -4.5 2.73 40.7 26.06 14.62 -4.5

Ecor1 Capital, Llc Ownership Network

Ownership Network List of Ecor1 Capital, Llc

No Data

Ownership Network Relation of Ecor1 Capital, Llc


Ecor1 Capital, Llc Owned Company Details

What does Surface Oncology Inc do?

Who are the key executives at Surface Oncology Inc?

Ecor1 Capital, Llc is the 10 percent owner of Surface Oncology Inc. Other key executives at Surface Oncology Inc include Deputy GC Chandra Adams , Chief Medical Officer Alison Oneill , and See Remarks Jessica Fees .

Surface Oncology Inc () Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Surface Oncology Inc (). Other recent insider transactions involving Surface Oncology Inc () include a net sale of 16,713 shares made by Robert W. Ross , a net sale of 9,434 shares made by Jessica Fees , and a net sale of 7,042 shares made by Alison Oneill .

In summary, during the past 3 months, insiders sold 0 shares of Surface Oncology Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,090 shares of Surface Oncology Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 37,090 shares.

Surface Oncology Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Surface Oncology Inc Insider Transactions

No Available Data

Ecor1 Capital, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Ecor1 Capital, Llc. You might contact Ecor1 Capital, Llc via mailing address: 357 Tehama Street #3, San Francisco Ca 94103.

Discussions on Ecor1 Capital, Llc

No discussions yet.